ArticleNature chemical biology2018
Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation.
Article in Nature chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Realizing the potential of agonistic antibody immunotherapy.Nature reviews. Drug discovery · 2026Review
- The Struggle Between Chimeric Antigen Receptor T-Cell Therapy and Neurological Complications in Acute Lymphoblastic Leukemia Treatment.Current issues in molecular biology · 2025Review
- Bioengineered therapeutic systems for improving antitumor immunity.National science review · 2025Review
- Synthetic living materials in cancer biology.Nature reviews bioengineering · 2023Article
- Applications of synthetic biology in medical and pharmaceutical fields.Signal transduction and targeted therapy · 2023Review
- Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting.Nature communications · 2023Article
- Droplet Microfluidics Enables Tracing of Target Cells at the Single-Cell Transcriptome Resolution.Bioengineering (Basel, Switzerland) · 2022Article
- Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells.Protein & cell · 2022Review
- Autonomous push button-controlled rapid insulin release from a piezoelectrically activated subcutaneous cell implant.Science advances · 2022Article
- Review
- The evolution of synthetic receptor systems.Nature chemical biology · 2022Review
- Engineering precision therapies: lessons and motivations from the clinic.Synthetic biology (Oxford, England) · 2021Review
- Building sophisticated sensors of extracellular cues that enable mammalian cells to work as "doctors" in the body.Cellular and molecular life sciences : CMLS · 2020Review
- Synthetic biology in various cellular and molecular fields: applications, limitations, and perspective.Molecular biology reports · 2020Review
- Programmable Synthetic Protein Circuits for the Identification and Suppression of Hepatocellular Carcinoma.Molecular therapy oncolytics · 2020Article
- Optogenetic regulation of endogenous proteins.Nature communications · 2020Article
- Elucidation and refinement of synthetic receptor mechanisms.Synthetic biology (Oxford, England) · 2020Article
- The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox.International journal of molecular sciences · 2019Review
- A cell topography-based mechanism for ligand discrimination by the T cell receptor.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Engineering advanced cancer therapies with synthetic biology.Nature reviews. Cancer · 2019Review
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
The ability to engineer custom cell-contact-sensing output devices into human nonimmune cells would be useful for extending the applicability of cell-based cancer therapies and for avoiding risks associated with engineered immune cells. Here we have developed a new class of synthetic T-cell receptor-like signal-transduction device that functions efficiently in human nonimmune cells and triggers release of output molecules specifically upon sensing contact with a target cell. This device employs an interleukin signaling cascade, whose OFF/ON switching is controlled by biophysical segregation of a transmembrane signal-inhibitory protein from the sensor cell-target cell interface. We further show that designer nonimmune cells equipped with this device driving expression of a membrane-penetrator/prodrug-activating enzyme construct could specifically kill target cells in the presence of the prodrug, indicating its potential usefulness for target-cell-specific, cell-based enzyme-prodrug cancer therapy. Our study also contributes to the advancement of synthetic biology by extending available design principles to transmit extracellular information to cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.